Features of metastasis and recurrence in patients with stromal cell ovarian tumors
https://doi.org/10.17650/2686-9594-2020-10-3-4-54-59
Abstract
Objective: a retrospective analysis of association of the tumor stage of stromal cell ovarian tumors with the frequency of recurrence and development of metastases in lymph nodes.
Materials and methods. 473 patients with stromal cell ovarian tumors with various histological types were examined, and long-term treatment results were evaluated.
Results. The highest recurrence rate (more than 80 %) was observed in stages II, III and IV. The frequency of development of metastases in the lymph nodes was highest in patients with stromal cell ovarian tumors of III–IV stages (50 %); however, in more than 40 % of cases of metastases in the lymph nodes was developed in patients with stromal cell ovarian tumors of IА, IВ, IС stages. The remaining 10 % of cases were in patients with stromal cell ovarian tumors of II stage. In patients with I stage without lymphadenectomy, metastases in the lymph nodes was developed in 21 % cases.
Conclusions. The high frequency of lymph node metastasis in patients with stromal cell ovarian tumors is a risk factor, which had to be evaluated to develop surgical treatment tactics.
About the Authors
A. M. Beyshembaev
Kyrgyz State Medical Institute of Retraining and Advanced Training named after S. B. Daniyarov, Ministry of Health of the Kyrgyz Republic
Kyrgyzstan
144A Bokonbaeva St., Bishkek 720064, Kyrgyz Republic
Kyrgyzstan
144A Bokonbaeva St., Bishkek 720064, Kyrgyz Republic
M. Sh. Temirova
Kyrgyz State Medical Institute of Retraining and Advanced Training named after S. B. Daniyarov, Ministry of Health of the Kyrgyz Republic
Kyrgyzstan
144A Bokonbaeva St., Bishkek 720064, Kyrgyz Republic
Kyrgyzstan
144A Bokonbaeva St., Bishkek 720064, Kyrgyz Republic
K. I. Zhordania
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
A. Yu. Kashurnikov
Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department
Russian Federation
9 Sharikopodshipnikovskaya St., Moscow 115088
Russian Federation
9 Sharikopodshipnikovskaya St., Moscow 115088
References
1. Beyshembaev A.M. Clinical and morphological characteristics of adult-type granulosa cell ovarian tumors. Zdravookhranenie Kyrgyzstana = Healthcare in Kyrgyzstan 2018;(3):22–5. (In Russ.). DOI: 10.17749/2313-7347.2019.13.4.289-296.
2. Situation with cancer care in Russia in 2018. Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: 2019. 231 p. (In Russ.).
3. Miura M., Suzuki S., Shibata K. et al. Estrogen producing ovarian fibrosarcoma: A case report. Nagoya J Med Sci 2019;81(1):171–6. DOI: 10.18999/nagjms.81.1.171.
4. Kozachenko V.P. Sex cord-gonadal stromal tumors. Onkoginekologiya = Gynecologic Oncology 2015;(4):41–7. (In Russ.).
5. Вu Bois A. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009;115:1234–44. DOI: 10.1002/cncr.24149.
6. Peiretti M., Zanagnolo V., Aletti G.D. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol 2010;119(2):259–64. DOI: 10.1016/j.ygyno.2010.07.032.
7. Chang S.J., Bristow R.E. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining “optimal” residual disease. Gynecol Oncol 2012;125(2):483–92. DOI: 10.1016/j.ygyno.2012.02.024.
8. Wimberger P., Wehling M., Lehmann N. et al. Influence of residual tumor on out-come in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 2010;17(6):1642–8. DOI: 10.1245/s10434-010-0964-9.
9. NCCN guidelines panel. Epithelial Ovarian Cancer. Version 1.2020. P. OV1. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian.
10. Harter P., Gnauert K., Hils R. et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 2007;17(6):1238–44. DOI: 10.1111/j.1525-1438.2007.00931.x.
11. May K., Bryant A., Dickinson H.O. et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010;(1):CD007585. DOI: 10.1002/14651858.CD007585.pub2.
12. Morice P., Joulie F., Camatte S. et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003;197(2):198–205. DOI: 10.1016/S1072-7515(03)00234-5.
13. Kang M., Lee K.B., Park Y.H., Cho H.Y. First reported case of intrahepatic cholangiocarcinoma metastasis to thecoma. J Obstet Gynaecol 2019;39(3):429–31. DOI: 10.1080/01443615.2018.1504901.
14. Boussios S., Zarkavelis G., Seraj E. et al. Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. Anticancer Res 2016;36(10):5031–42. DOI: 10.21873/anticanres.11072.
15. Ghosh A., Ghartimagar D., Thapa S. et al. Ovarian tumors: pattern of histomorphological types – a 10 years study in a tertiary referral center and review of literature. Kathmandu Univ Med J (KUMJ) 2016;14(54):153–8.
16. Payanidi Yu.G., Zhordania K.I., Kozachenko V.P. et al. Rehabilitation of patients with iatrogenic premature ovarian insufficiency. Onkoginekologiya = Gynecologic Oncology 2018;1(25):67–76. (In Russ.).
Review
Views:
562
Email this article 